|
Name |
Phomolactonexanthone A
|
Molecular Formula | C34H34O14 | |
IUPAC Name* |
[(2R)-8-[(5R,6R,10aR)-5-acetyloxy-1,9-dihydroxy-10a-(hydroxymethyl)-6-methyl-8-oxo-6,7-dihydro-5H-xanthen-2-yl]-5-hydroxy-2-[(2S,3S)-3-methyl-5-oxooxolan-2-yl]-4-oxo-3H-chromen-2-yl]methyl acetate
|
|
SMILES |
C[C@@H]1CC(=O)C2=C(C3=C(C=CC(=C3O)C4=C5C(=C(C=C4)O)C(=O)C[C@@](O5)(COC(=O)C)[C@@H]6[C@H](CC(=O)O6)C)O[C@@]2([C@@H]1OC(=O)C)CO)O
|
|
InChI |
InChI=1S/C34H34O14/c1-14-9-21(39)27-29(43)26-23(47-34(27,12-35)32(14)45-17(4)37)8-6-18(28(26)42)19-5-7-20(38)25-22(40)11-33(48-30(19)25,13-44-16(3)36)31-15(2)10-24(41)46-31/h5-8,14-15,31-32,35,38,42-43H,9-13H2,1-4H3/t14-,15+,31+,32-,33-,34+/m1/s1
|
|
InChIKey |
DRCRIEWXXYROPQ-VVISUSTOSA-N
|
|
Synonyms |
Phomolactonexanthone A
|
|
CAS | NA | |
PubChem CID | 139585097 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 666.6 | ALogp: | 2.4 |
HBD: | 4 | HBA: | 14 |
Rotatable Bonds: | 8 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 212.0 | Aromatic Rings: | 6 |
Heavy Atoms: | 48 | QED Weighted: | 0.256 |
Caco-2 Permeability: | -5.45 | MDCK Permeability: | 0.00001360 |
Pgp-inhibitor: | 0.594 | Pgp-substrate: | 0.299 |
Human Intestinal Absorption (HIA): | 0.682 | 20% Bioavailability (F20%): | 0.126 |
30% Bioavailability (F30%): | 0.826 |
Blood-Brain-Barrier Penetration (BBB): | 0.008 | Plasma Protein Binding (PPB): | 83.29% |
Volume Distribution (VD): | 0.6 | Fu: | 13.85% |
CYP1A2-inhibitor: | 0.062 | CYP1A2-substrate: | 0.054 |
CYP2C19-inhibitor: | 0.056 | CYP2C19-substrate: | 0.061 |
CYP2C9-inhibitor: | 0.352 | CYP2C9-substrate: | 0.332 |
CYP2D6-inhibitor: | 0.242 | CYP2D6-substrate: | 0.096 |
CYP3A4-inhibitor: | 0.77 | CYP3A4-substrate: | 0.263 |
Clearance (CL): | 1.825 | Half-life (T1/2): | 0.149 |
hERG Blockers: | 0.029 | Human Hepatotoxicity (H-HT): | 0.962 |
Drug-inuced Liver Injury (DILI): | 0.975 | AMES Toxicity: | 0.067 |
Rat Oral Acute Toxicity: | 0.913 | Maximum Recommended Daily Dose: | 0.213 |
Skin Sensitization: | 0.052 | Carcinogencity: | 0.115 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.01 |
Respiratory Toxicity: | 0.039 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002870 | 0.713 | D0T5XN | 0.277 | ||||
ENC005069 | 0.693 | D01XDL | 0.272 | ||||
ENC001973 | 0.650 | D01XWG | 0.272 | ||||
ENC003348 | 0.641 | D0C9XJ | 0.267 | ||||
ENC001969 | 0.639 | D07VLY | 0.267 | ||||
ENC001991 | 0.631 | D07IPB | 0.263 | ||||
ENC002978 | 0.630 | D0Q0PR | 0.263 | ||||
ENC002105 | 0.583 | D0FX2Q | 0.257 | ||||
ENC001968 | 0.565 | D01UBX | 0.255 | ||||
ENC005074 | 0.564 | D08LTU | 0.253 |